A Phase I/II Study of TRC105 in Combination With Sorafenib in Hepatocellular Carcinoma (HCC)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 02 May 2017
At a glance
- Drugs Carotuximab (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 02 May 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 10 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Jan 2018.